Focusing on the rare and aggressive cardiac sarcomas, our team identified several novel clinical markers by spatial transcriptomics, such as immunoglobulin kappa C (IGKC), procollagen C-endopeptidase enhancer (PCOLCE), Neuroepithelial transforming gene 1 (NET1), transducing-like enhancer protein 2 (TLE2), troponin C1 (TNNC1), and calponin 3 (CNN3), that classify normal heart tissue from sarcoma subtypes (47). This evidence concerns the gene TLE2 and sarcoma.